ArticleIntensive care medicine2013
Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia.
Article in Intensive care medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Hospital utilization rates for influenza and RSV: a novel approach and critical assessment.Population health metrics · 2021Pooled it
- Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and meta-analysis.Influenza and other respiratory viruses · 2020Pooled it
- Corticosteroids as adjunctive therapy in the treatment of influenza.The Cochrane database of systematic reviews · 2019Pooled it
- Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.Lancet (London, England) · 2020Trial
- Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study.PloS one · 2014Trial
- Article
- Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19.Healthcare (Basel, Switzerland) · 2023Article
- Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.Microbial drug resistance (Larchmont, N.Y.) · 2021Review
- Azithromycin in viral infections.Reviews in medical virology · 2021Review
- Critical care management of adults with community-acquired severe respiratory viral infection.Intensive care medicine · 2020Review
- Influenza Infections and Emergent Viral Infections in Intensive Care Unit.Seminars in respiratory and critical care medicine · 2019Review
- Macrolides in critically ill patients with Middle East Respiratory Syndrome.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2019Article
- Contemporary management of severe influenza disease in the intensive care unit.Journal of critical care · 2018Review
- The role of adjuvant immunomodulatory agents for treatment of severe influenza.Antiviral research · 2018Review
- Increased incidence of co-infection in critically ill patients with influenza.Intensive care medicine · 2017Article
- Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome.Critical care (London, England) · 2016Article
- Neces-SARI-ly?Intensive care medicine · 2016Article
- Antiviral combinations for severe influenza.The Lancet. Infectious diseases · 2014Review
- How to approach and treat viral infections in ICU patients.BMC infectious diseases · 2014Review
- Year in review in Intensive Care Medicine 2013: III. Sepsis, infections, respiratory diseases, pediatrics.Intensive care medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine whether macrolide-based treatment is associated with mortality in critically ill H1N1 patients with primary viral pneumonia.
methodsSecondary analysis of a prospective, observational, multicenter study conducted across 148 Intensive Care Units (ICU) in Spain.
resultsPrimary viral pneumonia was present in 733 ICU patients with pandemic influenza A (H1N1) virus infection with severe respiratory failure. Macrolide-based treatment was administered to 190 (25.9 %) patients. Patients who received macrolides had chronic obstructive pulmonary disease more often, lower severity on admission (APACHE II score on ICU admission (13.1 ± 6.8 vs. 14.4 ± 7.4 points, p < 0.05), and multiple organ dysfunction syndrome less often (23.4 vs. 30.1 %, p < 0.05). Length of ICU stay in survivors was not significantly different in patients who received macrolides compared to patients who did not (10 (IQR 4-20) vs. 10 (IQR 5-20), p = 0.9). ICU mortality was 24.1 % (n = 177). Patients with macrolide-based treatment had lower ICU mortality in the univariate analysis (19.2 vs. 28.1 %, p = 0.02); however, a propensity score analysis showed no effect of macrolide-based treatment on ICU mortality (OR = 0.87; 95 % CI 0.55-1.37, p = 0.5). Moreover, the sensitivity analysis revealed very similar results (OR = 0.91; 95 % CI 0.58-1.44, p = 0.7). A separate analysis of patients under mechanical ventilation yielded similar results (OR = 0.77; 95 % CI 0.44-1.35, p = 0.4).
conclusionOur results suggest that macrolide-based treatment was not associated with improved survival in critically ill H1N1 patients with primary viral pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.